NASDAQ:ECYT - Endocyte Stock Price, Price Target & More

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

Endocyte, Inc. (NASDAQ:ECYT) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.02 million for the quarter. Endocyte had a negative return on equity of 34.20% and a negative net margin of 70,510.81%. View Endocyte's Earnings History.

4 equities research analysts have issued 1-year target prices for Endocyte's stock. Their predictions range from $7.00 to $7.00. On average, they expect Endocyte's share price to reach $7.00 in the next twelve months. This suggests that the stock has a possible downside of 59.4%. View Analyst Ratings for Endocyte.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endocyte in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Endocyte saw a increase in short interest in June. As of June 29th, there was short interest totalling 8,046,703 shares, an increase of 125.7% from the June 15th total of 3,565,788 shares. Based on an average daily volume of 2,063,456 shares, the short-interest ratio is currently 3.9 days. Approximately 14.4% of the company's stock are short sold. View Endocyte's Current Options Chain.

Some companies that are related to Endocyte include Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), The Medicines (MDCO), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Intercept Pharmaceuticals (ICPT) and Horizon Pharma (HZNP).

News stories about ECYT stock have trended positive recently, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endocyte earned a news impact score of 0.28 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.74 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ECYT stock can currently be purchased for approximately $17.26.

Endocyte has a market capitalization of $1.20 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.